Privat-docent thesis

Efficacy and safety of intravitreal dexamethasone implant (Ozurdex®) in real-life practice

ContributorsMalcles, Arianeorcid
Number of pages81
Defense date2022-10-31

Millions of patients worldwide suffer from macular edema and associated loss of visual acuity. Luckily, the range of available treatments has widened over the past few years including the dexamethasone sustained-release implant (Ozurdex®) - a biodegradable intravitreal implant that maintains a high concentration of corticosteroids in the vitreous for up to 3 - 4 months. This progressive release decreases treatment burden compared to anti-VEGF that often require monthly injections.

We present the results of 3 real-life studies investigating the effects of Ozurdex® in diabetic macular edema (RELDEX study), non-infectious uveitis (RUVDEX study) and persistent postsurgical macular edema (EPISODIC 2 study).

A known side effect of steroids is ocular hypertension. Real-life studies SAFODEX 1 and 2 report new data on pressure tolerance of Ozurdex® and identify risk factors for ocular hypertension after dexamethasone implant offering scientific proof for better patient selection and follow-up.

  • Œdème maculaire
  • Dexamethasone
  • Traitement
Citation (ISO format)
MALCLES, Ariane. Efficacy and safety of intravitreal dexamethasone implant (Ozurdex®) in real-life practice. 2022. doi: 10.13097/archive-ouverte/unige:165897
Main files (1)

Technical informations

Creation11/04/2022 6:33:00 PM
First validation11/04/2022 6:33:00 PM
Update time03/16/2023 10:18:25 AM
Status update03/16/2023 10:18:25 AM
Last indexation02/01/2024 9:21:56 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack